| Title |
The Glutamatergic System and Alzheimer’s Disease
|
|---|---|
| Published in |
CNS Drugs, August 2012
|
| DOI | 10.2165/00023210-200317090-00004 |
| Pubmed ID | |
| Authors |
D. Allan Butterfield, Chava B. Pocernich |
| Abstract |
Alzheimer's disease affects nearly 5 million Americans currently and, as a result of the baby boomer cohort, is predicted to affect 14 million Americans and 22 million persons totally worldwide in just a few decades. Alzheimer's disease is present in nearly half of individuals aged 85 years. The main symptom of Alzheimer's disease is a gradual loss of cognitive function. Glutamatergic neurotransmission, an important process in learning and memory, is severely disrupted in patients with Alzheimer's disease. Loss of glutamatergic function in Alzheimer's disease may be related to the increase in oxidative stress associated with the amyloid beta-peptide that is found in the brains of individuals who have the disease. Therefore, therapeutic strategies directed at the glutamatergic system may hold promise. Therapies addressing oxidative stress induced by hyperactivity of glutamate receptors include supplementation with estrogen and antioxidants such as tocopherol (vitamin E) and acetylcysteine (N-acetylcysteine). Therapy for hypoactivity of glutamate receptors is aimed at inducing the NMDA receptor with glycine and cycloserine (D-cycloserine). Recently, memantine, an NMDA receptor antagonist that addresses the hyperactivity of these receptors, has been approved in some countries for use in Alzheimer's disease. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 232 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | <1% |
| United States | 2 | <1% |
| Netherlands | 1 | <1% |
| India | 1 | <1% |
| Austria | 1 | <1% |
| Canada | 1 | <1% |
| Australia | 1 | <1% |
| Unknown | 223 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 50 | 22% |
| Student > Master | 37 | 16% |
| Student > Bachelor | 30 | 13% |
| Student > Doctoral Student | 19 | 8% |
| Researcher | 17 | 7% |
| Other | 44 | 19% |
| Unknown | 35 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 51 | 22% |
| Neuroscience | 32 | 14% |
| Medicine and Dentistry | 29 | 13% |
| Biochemistry, Genetics and Molecular Biology | 18 | 8% |
| Chemistry | 17 | 7% |
| Other | 37 | 16% |
| Unknown | 48 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 June 2022.
All research outputs
#5,378,995
of 25,874,560 outputs
Outputs from CNS Drugs
#496
of 1,404 outputs
Outputs of similar age
#37,351
of 188,864 outputs
Outputs of similar age from CNS Drugs
#160
of 545 outputs
Altmetric has tracked 25,874,560 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,404 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,864 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 545 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.